GlassScriptPhysician profile
Gary B Boggs
NPI 1194219584
$2,927.85
in general payments reported to CMS, 2019-2025
22 companies · $833 in 2025
The $833 reported for 2025 was more than what 85% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $448 · 2022: $97.82 · 2023: $363 · 2024: $1,186 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,381.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $608.91 | 2021-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $341.47 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Mallinckrodt Hospital Products INC. | $244.29 | 2023-2025 | Acthar |
| Actelion Pharmaceuticals US, INC. | $227.08 | 2021-2024 | Uptravi, Opsumit |
| Genzyme Corporation | $179.23 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $169.08 | 2021-2025 | Dupixent |
| Janssen Pharmaceuticals, INC | $165.02 | 2021-2024 | Xarelto |
| Abiomed | $159.56 | 2024 | Impella |
| Paratek Pharmaceuticals, INC. | $158.90 | 2025 | Nuzyra, Xhance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.24 | 2021-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Abbott Laboratories | $134.42 | 2025 | Esprit |
| Mylan Specialty L.P. | $64.80 | 2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $61.96 | 2024-2025 | Glassia |
| United Therapeutics Corporation | $61.04 | 2021-2024 | Tyvaso |
| 3b Medical, INC. | $45.50 | 2024-2025 | Luna |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $32.76 | 2021 | |
| Insmed, INC. | $27.76 | 2024 | Arikayce |
| Viatris Specialty LLC | $27.13 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $16.43 | 2024 | Zerbaxa |
| Electromed, INC. | $15.90 | 2025 | Smartvest |
| Lilly USA, LLC | $15.62 | 2025 | Mounjaro, Zepbound |
| Tactile Systems Technology INC | $14.75 | 2025 | Flexitouch Plus, Nimbl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Boggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.